Company / Return on Equity (ROE)
Anika Therapeutics, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-7.6%
FY2025
5-year range
-39.0% / 9.4%
FY2021-FY2025
Trend
+79.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Anika Therapeutics, Inc. reports negative total equity of -7.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-7.6% in FY2025 with a 5-year CAGR of -14.7%.
Improved from -39.0% to -7.6% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +1.2pp
- 5-Year Change
- -14.7pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 79.3% year-over-year.
- Peak return on equity (roe) was recorded in FY2016.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -7.6% | +79.3% |
| FY2024 | -36.6% | +6.0% |
| FY2023 | -39.0% | -342.6% |
| FY2022 | -8.8% | -193.3% |
| FY2021 | 9.4% | +32.6% |
| FY2020 | 7.1% | -41.1% |
| FY2019 | 12.1% | -17.4% |
| FY2018 | 14.6% | +0.1% |
| FY2017 | 14.6% | -32.2% |
| FY2016 | 21.5% | +41.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026